fq
synthes
previous
cq
heparin
brefeldin
purchas
st
loui
fq
prepar
stock
solut
dimethyl
sulfoxid
dmso
cq
prepar
stock
solut
water
boceprevir
kindli
provid
philipp
halfon
ambrois
marseil
franc
celltrack
green
cmfda
diacet
invitrogen
molecular
probe
carlsbad
ca
cell
atcc
hela
cell
atcc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
bovin
kidney
cell
mdbk
atcc
cultur
dmem
supplement
glutamax
hors
serum
drug
toxic
cell
evalu
use
mt
assay
follow
recommend
manufactur
promega
madison
wi
monoclon
antibodi
mab
glycoprotein
glycoprotein
kindli
provid
j
mckeat
univers
birmingham
uk
fever
viru
yfv
envelop
protein
atcc
viral
diarrhea
viru
bvdv
protein
antibodi
ab
austral
biolog
san
ramon
ca
mab
bd
pharmingen
san
diego
ca
use
studi
alexa
phycoerythrin
pe
secondari
ab
jackson
immunoresearch
west
grove
pa
invitrogen
bd
pharmingen
respect
produc
hcv
hcvcc
use
modifi
version
plasmid
encod
japanes
fulmin
hepat
type
genom
genotyp
genbank
access
kindli
provid
wakita
nation
institut
infecti
diseas
tokyo
japan
briefli
hcvcc
produc
cell
electropor
rna
contain
renilla
luciferas
report
gene
engin
express
stock
produc
amplif
cell
construct
renilla
luciferas
gene
fuse
viral
open
read
frame
monocistron
configur
viru
verifi
luciferas
data
linear
rang
assay
plasmid
contain
delet
region
mutant
describ
inhibitori
effect
drug
determin
quantifi
infect
indirect
immunofluoresc
mab
measur
viral
titer
ab
quantit
bind
experi
purifi
viru
obtain
precipit
cell
supernat
polyethylen
glycol
pellet
viru
load
onto
continu
iodixanol
gradient
fraction
collect
infecti
fraction
pool
titer
stock
focu
form
unit
ffu
ml
hcv
pseudotyp
retrovir
particl
hcvpp
express
firefli
luciferas
report
gene
produc
previous
intergenotyp
hcv
chimera
also
use
experi
furthermor
bvdv
strain
nadl
yfv
strain
also
use
test
effect
compound
virus
hcv
transmiss
measur
two
differ
approach
previous
infect
cell
grown
glass
coverslip
process
detect
viral
protein
previous
nuclei
stain
coverslip
observ
zeiss
axiophot
microscop
carl
zeiss
oberkochen
germani
fluoresc
signal
collect
coolsnap
es
camera
photometrix
kew
australia
quantif
cell
imag
randomli
pick
area
coverslip
record
cell
inocul
hour
hcvcc
plate
indic
time
hcv
core
antigen
express
within
cell
secret
supernat
quantifi
use
chemiluminesc
microparticl
technolog
architect
hcv
ag
test
abbott
diagnost
rungi
franc
previous
virion
bound
cell
determin
quantit
polymeras
chain
reaction
assay
describ
intern
measur
previous
cell
treat
fq
hour
incub
fq
cell
stain
ab
flow
cytometri
andor
western
blot
previous
fusion
assay
perform
previous
supernat
cell
serial
passag
increas
concentr
fq
structur
region
hcv
genom
amplifi
sequenc
amino
acid
chang
aros
inhibitor
select
identifi
analysi
dna
sequenc
compar
initi
control
passag
presenc
solvent
alon
identifi
mutat
reintroduc
plasmid
pcr
mutagenesi
plasmid
sequenc
antivir
activ
rang
fq
concentr
alon
combin
boceprevir
determin
measur
inhibitori
concentr
valu
combin
index
calcul
accord
previous
report
prichard
shipman
also
use
analyz
interact
effect
use
approach
method
present
complet
drug
interact
prism
softwar
graphpad
softwar
inc
la
jolla
ca
use
prepar
graph
calcul
valu
determin
statist
signific
differ
data
set
chemic
structur
fq
cq
present
fig
test
effect
fq
hcv
life
cycl
compound
ad
target
cell
well
infect
fq
exhibit
inhibit
hcv
indic
fq
specif
affect
hcv
life
cycl
estim
valu
inhibitori
concentr
fig
similar
result
obtain
use
cell
line
express
data
shown
inhibitori
effect
result
cytotox
parallel
experi
show
toxic
effect
drug
concentr
test
support
fig
furthermor
cytotox
observ
primari
human
hepatocyt
concentr
use
experi
support
fig
fq
show
cytotox
concentr
therapeut
index
similar
inhibitori
effect
observ
cell
infect
chimer
viru
contain
structur
protein
genotyp
isol
support
fig
indic
antivir
effect
specif
isol
parallel
control
experi
hcv
inhibitor
present
support
fig
cq
less
effect
hcv
fig
e
inde
valu
cq
respect
furthermor
cq
therapeut
index
determin
whether
hcv
member
flavivirida
famili
affect
fq
test
compound
two
member
viral
famili
bvdv
yfv
bvdv
yfv
infect
perform
mdbk
cell
respect
fq
show
antivir
effect
two
virus
albeit
much
higher
concentr
inde
valu
bvdv
yfv
respect
altogeth
result
indic
fq
potent
antivir
activ
hcv
determin
whether
fq
effect
hcv
entri
compound
ad
remov
differ
time
point
inocul
cell
fig
highest
decreas
hcvcc
infect
observ
fq
present
viral
infect
weak
antivir
effect
detect
fq
ad
postinfect
fig
b
similar
result
obtain
cq
fig
parallel
control
experi
hcv
inhibitor
present
support
fig
result
suggest
fq
inhibit
earli
step
hcv
life
cycl
like
entri
step
investig
effect
fq
hcv
entri
use
hcvpp
system
retrovir
core
carri
hcv
glycoprotein
envelop
context
earli
step
viral
life
cycl
ie
viru
interact
receptor
uptak
fusion
hcv
specif
wherea
later
step
depend
retrovir
nucleocapsid
element
use
approach
fq
inhibit
hcvpp
entri
manner
fig
furthermor
effect
specif
hcv
envelop
glycoprotein
fq
affect
entri
control
pseudoparticl
contain
envelop
glycoprotein
felin
endogen
retroviru
togeth
data
indic
fq
inhibitor
hcv
entri
fq
specif
affect
hcv
entri
prompt
us
test
antivir
effect
differ
hcv
genotyp
subtyp
context
hcvpp
system
fq
inhibit
infect
hcvpp
differ
genotyp
subtyp
test
indic
fq
inhibit
hcv
entri
manner
tabl
although
data
indic
fq
strong
effect
hcv
entri
exclud
addit
effect
step
hcv
life
cycl
analyz
effect
fq
hcv
genom
replic
cell
electropor
rna
bypass
entri
step
avoid
interfer
late
step
hcv
life
cycl
furthermor
boceprevir
use
parallel
control
inhibit
viral
replic
fq
also
effect
hcv
replic
fig
albeit
higher
concentr
see
fig
observ
agreement
addit
weak
antivir
effect
detect
fq
ad
postinfect
fig
determin
whether
fq
could
effect
hcv
assembl
secret
extracellular
core
protein
quantifi
infect
cell
treat
postinfect
fq
amount
core
cultur
supernat
reflect
quantiti
secret
viral
particl
amount
core
releas
supernat
infect
cell
significantli
reduc
presenc
fq
treatment
fig
contrast
brefeldin
inhibitor
hcv
releas
reduc
core
secret
data
show
fq
inhibit
virion
assembl
egress
data
show
fq
antivir
activ
earli
step
hcv
life
cycl
investig
mode
action
hcv
entri
determin
whether
fq
impair
directli
bind
particl
cell
surfac
analyz
viru
bind
presenc
fq
cell
inocul
purifi
hcvcc
presenc
fq
amount
bound
virion
determin
quantifi
hcv
genom
rna
grna
heparin
use
control
inhibit
hcv
bind
expect
heparin
strongli
reduc
hcv
attach
cell
surfac
fig
presenc
fq
effect
viru
bind
observ
fig
indic
fq
inhibit
hcv
entri
impair
viru
bind
cell
surfac
analyz
mechan
fq
inhibit
hcv
entri
assess
express
known
essenti
hcv
entri
factor
ocln
cell
treat
fq
hour
ocln
express
assess
western
blot
andor
flow
cytometri
express
level
four
entri
factor
unalt
indic
fq
act
fig
c
fq
inhibit
bind
hcv
particl
cell
surfac
effect
express
hcv
receptor
also
analyz
effect
molecul
intern
viral
particl
hcv
intern
affect
fq
treatment
indic
molecul
block
postintern
step
fig
also
worth
note
fq
effect
ifn
induct
support
fig
determin
effect
fq
fusion
process
use
fusion
assay
previous
fq
induc
decreas
fusion
activ
hcv
envelop
glycoprotein
wherea
effect
observ
control
chikungunya
viru
envelop
glycoprotein
fig
togeth
result
indic
fq
inhibit
fusion
step
hcv
entri
process
investig
mechan
action
fq
select
partial
resist
mutant
propag
sever
passag
presenc
increas
concentr
drug
passag
observ
amino
acid
chang
wherea
two
mutat
identifi
glycoprotein
interestingli
revers
genet
experi
indic
mutat
abl
confer
resist
fq
fig
worth
note
serin
well
conserv
genotyp
subsequ
infect
cell
hcvcc
progeni
virus
transmit
adjac
cell
result
focal
area
spread
infect
foci
mode
transmiss
refractori
neutral
determin
whether
fq
block
spread
cell
cocultur
cell
presenc
absenc
fq
previous
fig
second
approach
cell
label
cmfda
cocultur
target
cell
presenc
absenc
fq
previous
fig
strong
decreas
transmiss
clearli
observ
approach
fig
test
whether
fq
could
combin
compound
current
use
hepat
c
treatment
use
boceprevir
drug
target
directli
hcv
proteas
use
sever
decad
treatment
drug
combin
analyz
use
combin
index
ci
well
prichard
shipman
drug
combin
fq
differ
fraction
valu
combin
fq
boceprevir
result
addit
effect
reflect
ci
respect
furthermor
synergi
also
observ
higher
concentr
measur
prichard
shipman
fig
hcv
entri
repres
attract
target
antivir
intervent
opportun
prevent
multipl
interact
interfer
membran
studi
show
fq
exhibit
antivir
activ
hcv
inhibit
postbind
postintern
step
hcv
entri
target
cell
block
spread
neighbor
cell
although
fq
analog
cq
mechan
action
potenti
mechan
inhibit
cq
involv
impair
viru
entri
like
prevent
endocytosi
andor
endosom
acidif
contrast
fq
weaker
base
properti
compar
differ
could
potenti
explain
lack
antivir
activ
fq
virus
vesicular
stomat
viru
influenza
viru
sindbi
wherea
cq
block
cell
entri
virus
well
interest
featur
fq
higher
lipophil
ph
peculiar
conform
provid
intramolecular
hydrogen
bond
present
nonpolar
condit
result
better
potenc
fq
cross
addit
fq
also
shown
specif
gener
reactiv
oxygen
speci
induc
lipid
recent
shown
hcv
envelop
protein
form
larg
molecular
complex
stabil
intermolecular
disulfid
observ
strongli
suggest
entri
process
necessit
rearrang
disulfid
bond
fusion
process
take
place
therefor
possibl
oxid
properti
fq
acid
condit
could
inhibit
fusion
process
affect
reorgan
disulfid
bond
within
endosom
fq
inhibit
postbind
postintern
step
hcv
entri
target
cell
inde
fq
affect
bind
hcvcc
cell
express
specif
cellular
entri
factor
furthermor
effect
fq
hcvpp
strongli
suggest
fq
affect
entri
function
hcv
envelop
protein
lipoprotein
moieti
associ
virion
data
also
show
fq
block
hcv
entri
inhibit
fusion
process
final
mutat
identifi
work
suggest
could
target
fq
addit
effect
hcv
entri
fq
also
affect
hcv
rna
replic
albeit
higher
concentr
inhibitori
effect
similar
inhibit
hcv
subgenom
replicon
hcv
known
exploit
autophagi
inhibit
replic
cq
target
howev
remain
determin
whether
inhibit
hcv
rna
replic
fq
depend
mechan
clinic
studi
healthi
human
volunt
shown
fq
safe
well
toler
oral
dose
mg
fq
mean
estim
blood
appar
termin
fq
addit
maximum
blood
concentr
ngml
observ
highest
dose
fq
slightli
valu
calcul
hcv
cell
cultur
although
concentr
would
probabl
high
enough
elimin
hcv
complet
would
like
suffici
combin
therapi
drug
show
synergist
addit
effect
studi
necessari
determin
vivo
potenc
fq
hcv
fq
may
provid
new
approach
prevent
hcv
infect
especi
set
liver
transplant
lt
chronic
infect
hcv
patient
inde
major
problem
lt
result
hcv
reinfect
graft
alway
observ
acceler
progress
liver
thu
abil
fq
inhibit
hcv
transmiss
major
asset
entri
inhibitor
furthermor
fq
exhibit
antivir
activ
hcv
genotyp
test
hcvpp
system
increas
potenti
interest
gener
agent
combin
entri
replic
inhibitor
context
multidrug
therapi
might
way
reduc
risk
emerg
resist
virus
fq
might
thu
valuabl
option
test
combin
final
find
highlight
potenti
interest
fq
use
countri
malaria
coinfect
hcv
occur
